Biodesix (NASDAQ:BDSX – Get Free Report) is scheduled to release its earnings data before the market opens on Friday, November 1st. Analysts expect Biodesix to post earnings of ($0.08) per share for the quarter. Biodesix has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Biodesix (NASDAQ:BDSX – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. The business had revenue of $17.93 million during the quarter, compared to analysts’ expectations of $16.05 million. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, analysts expect Biodesix to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Biodesix Price Performance
Shares of NASDAQ:BDSX opened at $1.63 on Friday. The company has a 50-day simple moving average of $1.75 and a 200-day simple moving average of $1.59. Biodesix has a one year low of $1.15 and a one year high of $2.21. The company has a debt-to-equity ratio of 0.99, a quick ratio of 3.28 and a current ratio of 3.28. The stock has a market capitalization of $186.94 million, a price-to-earnings ratio of -2.96 and a beta of 1.22.
Analysts Set New Price Targets
Get Our Latest Report on Biodesix
Biodesix Company Profile
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
See Also
- Five stocks we like better than Biodesix
- CD Calculator: Certificate of Deposit Calculator
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Stock Market Sectors: What Are They and How Many Are There?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Following Congress Stock Trades
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.